Tecentriq combo delivers survival benefit to NSCLC patients

A Phase III study by Genentech has met its co-primary endpoint of overall survival at interim analysis and demonstrated that first-line treatment with the combination of Tecentriq® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped patients with advanced non-squamous non-small cell lung cancer live significantly longer compared with Avastin plus carboplatin and paclitaxel.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please Login or Register to view this area.

drug development non-small-cell lung cancer pharma Phase III